We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Chattem, Inc. (MM) | NASDAQ:CHTT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 93.49 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
French drug company Sanofi-Aventis (SNY) Thursday said it has completed the acquisition of 100% of Chattem, Inc. (CHTT), which is now a wholly-owned subsidiary of the Sanofi-Aventis Group.
MAIN FACTS:
- Sanofi-Aventis said the acquisition provides new channels for maximizing the potential of converting its prescription medicines to over-the-counter, or OTC, products, beginning with Allegra, which it expects to be an important growth driver.
- The transaction is expected to be accretive to Sanofi-Aventis' earnings as early as year one.
- Sanofi Aventis also said it expects to obtain significant revenue synergies through the expansion of Chattem's products into currently untapped geographic markets where Sanofi-Aventis has a strong operating presence.
- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; djnews.paris@dowjones.com
1 Year Chattem, Inc. (MM) Chart |
1 Month Chattem, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
